Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2010

01-08-2010 | Personal View

Is there an impatience genotype leading to non-adherence to long-term therapies?

Author: G. Reach

Published in: Diabetologia | Issue 8/2010

Login to get access

Abstract

In chronic diseases such as diabetes, adherence to therapy aims to preserve health, which is a long-term objective, whereas non-adherence tends to present an immediate ‘reward’. We propose that non-adherence, like addiction, is at least in part due to the fact that, for physiological, and maybe genetic reasons described in a new field, neuroeconomics, a number of people have a taste for the present rather than the future. Thus, for ‘impatient patients’ it is natural not to adhere to therapeutic prescriptions that share the characteristic of being future-oriented. This hypothesis may apply to any disease requiring long-term therapy.
Literature
1.
Report WHO (2003) Adherence to long term therapies, evidence for action. World Health Organization Publications, Geneva
2.
Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA (2006) Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 12:466–471PubMed
3.
Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS (2008) Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 14:71–75PubMed
4.
Ho PM, Rumsfeld JS, Masoudi FA et al (2006) Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 166:1836–1841CrossRefPubMed
5.
Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL (2006) Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 19:31–41PubMed
6.
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS (2005) Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43:521–530CrossRefPubMed
7.
Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437–443CrossRefPubMed
8.
Harrold LR, Andrade SE, Briesacher BA et al (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11:R46CrossRefPubMed
9.
Kalenscher T, Pennartz C (2008) Is a bird in the hand worth two in the future? The neuroeconomics of intertemporal decision-making. Prog Neurobiol 84:284–315PubMed
10.
Rachlin H, Raineri A, Cross D (1991) Subjective probability and delay. J Exp Anal Behav 55:233–244CrossRefPubMed
11.
Bickel WK, Johnson MW (2003) Delay discounting: a fundamental behavioural process of drug dependence. In: Loewenstein G, Read D, Baumeister RF (eds) Time and decision. Russel Sage Foundation, New York, pp 419–440
12.
13.
Elster J, Skog OJ (1999) Getting hooked, rationality and addiction. Cambridge University Press, Cambridge
14.
Johnson MW, Bickel WK, Baker F (2007) Moderate drug use and delay discounting: a comparison of heavy, light, and never smokers. Exp Clin Psychopharmacol 15:187–194CrossRefPubMed
15.
Mitchell JM, Fields HL, D’Esposito M, Boettiger CA (2005) Impulsive discounting in alcoholics. Alcohol Clin Exp Res 29:2158–2169PubMed
16.
Perry JL, Carroll ME (2008) The role of impulsive behavior in drug abuse. Psychopharmacology 200:1–26CrossRefPubMed
17.
Takahashi T, Oono H, Inoue T et al (2008) Depressive patients are more impulsive and inconsistent in intertemporal choice behavior for monetary gain and loss than healthy subjects—an analysis based on Tsallis’ statistics. Neuro Endocrinol Lett 29:351–358PubMed
18.
Weller RE, Cook EW III, Aswar KB, Cox JE (2008) Obese women show greater delay discounting than healthy-weight women. Appetite 51:563–569CrossRefPubMed
19.
Bickel WK, Miller ML, Yi R, Kowal BP, Lindquist DM, Pitcock JA (2007) Behavioral and neuroeconomics of drug addiction: competing neural systems and temporal discounting processes. Drug Alcohol Depend 90(Suppl 1):S85–S91CrossRefPubMed
20.
Boettiger CA, Mitchell JM, Tavares VC et al (2007) Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyltransferase 158val/val genotype. J Neurosci 27:14383–14391CrossRefPubMed
21.
Manuck SB, Flory JD, Ferrell RE, Mann JJ, Muldoon MF (2000) A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatry Res 95:9–23CrossRefPubMed
22.
Shaw P, Wallace GL, Addington A, Evans A, Rapoport J, Giedd JN (2009) Effects of the Val158Met catechol-O-methyltransferase polymorphism on cortical structure in children and adolescents. Mol Psychiatry 14:348–349CrossRefPubMed
23.
Elster J (1977) Ulysses and the Sirens: a theory of imperfect rationality. Soc Sci Inf 16:469–526CrossRef
24.
Southam L, Soranzo N, Montgomery SB et al (2009) Is the thrifty genotype hypothesis supported by evidence based on confirmed type 2 diabetes- and obesity-susceptibility variants? Diabetologia 52:1846–1851CrossRefPubMed
25.
Bickel WK, Pitcock JA, Yi R, Angtuaco EJ (2009) Congruence of BOLD response across intertemporal choice conditions: fictive and real money gains and losses. J Neurosci 29:8839–8846CrossRefPubMed
26.
Ainslie G (2001) Breakdown of will. Cambridge University Press, New York
27.
Reynolds B (2006) A review of delay-discounting research with humans: relation to drug use and gambling. Behav Pharmacol 17:661–667
28.
Monterosso J, Ainslie G (2007) The behavioral economics of will in recovery from addiction. Drug Alcohol Depend 90(Suppl 1):S100–S111CrossRefPubMed
29.
Chapman GB, Brewer NT, Coups EJ, Browlee S, Leventhal H, Leventhal EA (2001) Value for the future and preventive health behavior. J Exp Psychol Appl 7:235–250CrossRefPubMed
30.
Solberg LI, Boyle RG, McCarty M, Asche SE, Thoele MJ (2004) Diabetic patients who smoke: are they different? Ann Fam Med 2:26–32CrossRefPubMed
31.
Perros P, Deary IJ, Frier BM (1998) Factors influencing preference of insulin regimen in people with type 1 (insulin-dependent) diabetes. Diabet Res Clin Pract 39:23–29CrossRef
32.
Curtis JR, Xi J, Westfall AO et al (2009) Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 47:334–341CrossRefPubMed
33.
Ahmed AT, Karter AJ, Liu J (2006) Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours. Diabet Med 23:795–802CrossRefPubMed
34.
Brookhart MA, Patrick AR, Dormuth C et al (2007) Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166:348–354CrossRefPubMed
35.
Gurmankin Levy A, Micco E, Putt M, Armstong K (2006) Value for the future and breast cancer-preventive health behaviour. Cancer Epidemiol Biomarkers Prev 15:955–960CrossRefPubMed
36.
Bickel WK, Yi R, Kowal BP, Gatchalian KM (2008) Cigarette smokers discount past and future rewards symmetrically and more than controls: is discounting a measure of impulsivity? Drug Alcohol Depend 96:256–262CrossRefPubMed
37.
Wallace M (1956) Future time perspective in schizophrenia. J Abnorm Psychology 52:240–245CrossRef
38.
Jones BA, Landes RD, Yi R, Bickel WK (2009) Temporal horizon: modulation by smoking status and gender. Drug Alcohol Depend 104(Suppl 1):S87–S93CrossRefPubMed
39.
Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV (2000) Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care 23:477–483CrossRefPubMed
40.
Frederick S (2003) Time preference and personal identity. In: Loewenstein G, Read D, Baumeister RF (eds) Time and decision. Russel Sage Foundation, New York, pp 89–113
41.
Stilley CS, Lawrence K, Bender A, Olshansky E, Webber SA, Dew MA (2006) Maturity and adherence in adolescent and young adult heart recipients. Pediatr Transplant 10:323–330CrossRefPubMed
42.
Giedd JN (2004) Adolescent brain development: vulnerabilities and opportunities. Ann N Y Acad Sci 1021:77–85CrossRefPubMed
43.
Galvan A, Hare TA, Parra CE et al (2006) Earlier development of the accumbens relative to orbitofrontal cortex might underlie risk-taking behavior in adolescents. J Neurosci 26:6885–6892CrossRefPubMed
44.
Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G (2007) Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care 19:134–140CrossRefPubMed
45.
Keller DL, Wright J, Pace HA (2008) Impact of health literacy on health outcomes in ambulatory care patients: a systematic review. Ann Pharmacother 42:1272–1281CrossRefPubMed
46.
Simpson SH, Eurich DT, Majumdar SR et al (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15CrossRefPubMed
47.
Kalis A, Mojzisch A, Schweizer TS, Kaiser S (2008) Weakness of will, akrasia, and the neuropsychiatry of decision making: an interdisciplinary perspective. Cogn Affect Behav Neurosci 8:402–417CrossRefPubMed
Metadata
Title
Is there an impatience genotype leading to non-adherence to long-term therapies?
Author
G. Reach
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1755-3

Other articles of this Issue 8/2010

Diabetologia 8/2010 Go to the issue

Article

Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study

Article

Variants at DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B loci are associated with reduced glucose-stimulated beta cell function in middle-aged Danish people

Review

The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence

Article

Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet

Article

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure

Article

Mitochondrial fragmentation and superoxide anion production in coronary endothelial cells from a mouse model of type 1 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits